Scarica l'app Stockscreener
0.00
100.00%
-53.01
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Soleno Therapeutics Inc Borsa (SLNO) Ultime notizie
Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Soleno Therapeutics (NASDAQ: SLNO) deregisters 3,000,000-share resale after merger - Stock Titan
News On Soleno Therapeutics Inc. (SLNO) Now Under NBIX - Moomoo
Soleno Therapeutics, Inc.(NasdaqGM: ) dropped from Russell 3000E Index - marketscreener.com
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics - Sahm
Neurocrine Biosciences Finalizes $2.9 Billion Acquisition of Soleno Therapeutics - Moomoo
Merger cashes out Soleno (NASDAQ: SLNO) officer equity at $53 - Stock Titan
Soleno Therapeutics (SLNO) director’s shares and options cancelled for $53 cash in Neurocrine merger - Stock Titan
Soleno Therapeutics (SLNO) director equity canceled in $53-per-share merger - Stock Titan
Soleno (SLNO) director’s shares cashed out at $53 per-share merger price - Stock Titan
Soleno Therapeutics (SLNO) CBO equity canceled, cashed out at $53 per share - Stock Titan
Soleno Therapeutics (SLNO) CCO equity cancelled, converted to $53 cash in merger - Stock Titan
Soleno Therapeutics (SLNO) CDO equity cancelled for $53 cash in merger - Stock Titan
Soleno (SLNO) SVP exits equity as merger pays $53 per share - Stock Titan
Soleno Therapeutics (SLNO) insider equity cashed out at $53 in Neocrine merger - Stock Titan
Soleno (SLNO) director’s 10,046 RSUs canceled for $53 cash in merger - Stock Titan
Soleno Therapeutics (SLNO) CFO has RSUs and stock options cashed out in Neocrine merger - Stock Titan
Soleno Therapeutics (SLNO) director exits as $53-per-share cash merger closes - Stock Titan
Soleno Therapeutics (SLNO) CEO fully cashed out as $53-per-share merger closes - Stock Titan
Neurocrine Biosciences completes $2.9 billion Soleno acquisition - Investing.com UK
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B - Contract Pharma
Neurocrine Biosciences, Inc. completed the acquisition of Soleno Therapeutics, Inc. from Anish Bhatnagar, James Mackaness, and others. - marketscreener.com
Neurocrine Biosciences Acquires Soleno Therapeutics, Adds VYKAT XR for Prader-Willi Syndrome to Rare Disease Portfolio - Minichart
Soleno Therapeutics Announces Acquisition by Neurocrine Biosciences and Corporate Changes – SEC Form 8-K Filing - Minichart
Soleno Therapeutics completes merger with Neurocrine Biosciences, delists from Nasdaq - Investing.com Nigeria
Neurocrine Closes $2.9 Billion Soleno Acquisition to Expand Rare Disease Portfolio - citybiz
Neurocrine Biosciences completes $2.9 billion Soleno acquisition By Investing.com - Investing.com Australia
Neurocrine Biosciences completes acquisition of Soleno Therapeutics - marketscreener.com
Neurocrine Biosciences Completes Acquisition Of Soleno Therapeutics - TradingView
Soleno Therapeutics (NASDAQ: SLNO) taken private at $53 per share in cash deal - Stock Titan
Soleno Therapeutics (NASDAQ: SLNO) deregisters S-3 after Neurocrine merger - Stock Titan
Soleno Therapeutics (SLNO) Nasdaq submits Form 25 to remove common stock - Stock Titan
Soleno Therapeutics, Inc. Announces Resignation of Anish Bhatnagar, M.D. as Chief Executive Officer, Effective May 18, 2026 - marketscreener.com
Neurocrine Biosciences (NASDAQ: NBIX) completes $2.9B Soleno acquisition - Stock Titan
Neurocrine completes Soleno buyout (NASDAQ: SLNO) at $53.00 per share - Stock Titan
Neurocrine (SLNO) completes tender offer; ~46.36M Soleno shares tendered - Stock Titan
Press Release: Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics - Moomoo
Soleno Therapeutics, Inc. (SLNO) Stock Report: A Biotech Player with Steady ROE and Strategic Focus on Rare Diseases - DirectorsTalk Interviews
Neurocrine to buy Soleno Therapeutics for $2.9 billion - MSN
Soleno Therapeutics, Inc.(NasdaqCM: SLNO) dropped from S&P Global BMI Index - marketscreener.com
Soleno Therapeutics, Inc.(NasdaqCM:SLNO) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Soleno Therapeutics, Inc.(NasdaqCM: SLNO) dropped from S&P TMI Index - marketscreener.com
Soleno Therapeutics, Inc.(NasdaqGM: SLNO) dropped from NASDAQ Composite Index - marketscreener.com
The Technical Signals Behind (SLNO) That Institutions Follow - Stock Traders Daily
T. Rowe Price (NASDAQ: SLNO) reports 1,025,868 shares, 2.0% stake - Stock Titan
Avoro and Aghazadeh report 4.45% stake in Soleno (NASDAQ: SLNO) - Stock Titan
Wellington affiliates disclose 8.57% stake in Soleno Therapeutics (SLNO) - Stock Titan
Neurocrine reaffirms $2.7B-$2.8B INGREZZA outlook while acquisition of Soleno remains on track for Q2 close - MSN
State Street (SLNO) holds 2.68M shares, 5.2% stake in Soleno Therapeutics - Stock Titan
SLNO 8-DAY DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Securities Class Action Alleging Hyperphagia Drug Launch DisruptionsHagens Berman - PR Newswire
Soleno Therapeutics faces final earnings test before buyout By Investing.com - Investing.com South Africa
Soleno Therapeutics faces final earnings test before buyout - Investing.com
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: A Strategic Hold in the Biotech Space with Steady Potential - DirectorsTalk Interviews
Soleno Merger With Neurocrine Puts Profitability And Valuation In Focus - Yahoo Finance
Number of shareholders of Soleno Therapeutics, Inc. – NASDAQ:SLNO - TradingView
MSN Money - MSN
Lobbying Update: $80,000 of SOLENO THERAPEUTICS INC. lobbying was just disclosed - Quiver Quantitative
2.25%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):